April 2, 2014
Impax Laboratories, Inc.
today announced that
Jeffrey D. Nornhold
has been appointed Senior Vice President, Technical Operations and will oversee the Company's manufacturing, supply chain, quality and technical operations. Mr. Nornhold previously served as the Company's Senior Vice President, Global Quality Affairs since
, Senior Vice President, Global Operations announced his plans to retire, but will continue to work with Nornhold to ensure a smooth transition. Since joining Impax in June of 2011, Fitch has partnered with Nornhold to enhance the Company's manufacturing and quality areas, and improve operating efficiencies. This includes improvements to the Company's
facility, expansion of the
facility, the transfer of numerous currently approved and manufactured products from
and building a highly qualified leadership team.
"Working alongside Mark the past three years has been a great experience," said Nornhold. "We have collaborated on enhancing and improving the critical areas of quality, manufacturing and compliance."
"Jeff has done an outstanding job of building a highly skilled internal quality organization and establishing the foundation for sustainable quality and compliance", said
, Ph.D., President and CEO of Impax Laboratories. "We believe Jeff is the ideal person to manage this new structure, and effectively drive compliance, efficiencies and collaboration across these key business functions."
Mr. Nornhold has over 24 years of experience in pharmaceutical manufacturing and related technical operations. Prior to joining Impax in 2011, he gained a significant amount of Technical Operations experience at Watson Pharmaceuticals (now Actavis plc), serving as Vice President, Quality Operations - International, and was responsible for manufacturing sites for both dosage and active pharmaceutical ingredients outside of the U.S. He also served as Vice President, U.S. Quality Operations at Watson, leading the development and execution of quality initiatives for all U.S. sites. Prior to joining Watson in 2000, he held numerous leadership positions within the pharmaceuticals industry.